Pfizer Pflat In 2005: Revenue Will Be "Substantially Unchanged"
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer expects flat revenue growth during 2005 in the face of patent expirations and the poor performance of its COX-2 inhibitors